Show simple item record

dc.contributor.authorBracken, Tara Catherine
dc.date.accessioned2017-03-31T04:31:56Z
dc.date.available2017-03-31T04:31:56Z
dc.date.issued2016-12
dc.identifier.otherbracken_tara_c_201612_phd
dc.identifier.urihttp://purl.galileo.usg.edu/uga_etd/bracken_tara_c_201612_phd
dc.identifier.urihttp://hdl.handle.net/10724/36939
dc.description.abstractMalaria poses a serious threat to global health, with 3.2 billion people in 95 countries at risk of infection. Pregnant women and young children in malaria-endemic areas bear the heaviest burden of malaria infection due to two severe clinical manifestations of malaria, placental (PM) and cerebral malaria (CM) resulting from sequestration of infected erythrocytes in the maternal blood space of the placenta or the brain. The use of adjunctive therapies to specifically target pathogenic processes known to occur during PM and CM hold great promise to prevent the more serious outcomes of malaria infection. However, to date, therapies targeting the best-understood contributor to malaria pathogenesis — inflammation — have so far been unsuccessful. Previous experiments in our lab and evidence in the clinical literature have shown that a potently procoagulant state exists during PM and CM, and that suppression of that state with a research-grade low molecular weight heparin could mitigate mid-gestational pregnancy loss during murine placental malaria infection. These studies indicated activated coagulation was an important contributor to malaria pathogenesis, but which components of the coagulation cascade were relevant to the observed pathologies remained unclear. This dissertation, therefore, sought to build upon that work by identifying members of the extrinsic pathway of coagulation contributing to malaria pathogenesis and by assessing the potential of anticoagulant therapy to mitigate severe clinical outcomes of malaria. We began using Cre-lox technology to induce tissue-specific deletions of Tissue Factor, the initiator of the extrinsic pathway of coagulation, to identify tissue types contributing to this damaging procoagulant state. We then tested two anticoagulants currently approved for clinical use in humans — the low molecular weight heparin, Dalteparin, and the coagulation FXa inhibitor, Fondaparinux — to assess how blocking the coagulation cascade affects disease progression and outcome. This dissertation also includes an assessment of naturally acquired Helicobacter infection in laboratory mouse colonies and how such infections may interfere with mouse models of disease in pregnancy. The results here presented provide compelling evidence that anticoagulant drugs have the potential to serve as useful adjunctive therapies for the treatment of both placental and cerebral malaria.
dc.languageeng
dc.publisheruga
dc.rightsOn Campus Only Until 2018-12-01
dc.subjectPlasmodium falciparum
dc.subjectplacental malaria
dc.subjectcerebral malaria
dc.subjectcoagulation
dc.subjectanticoagulant therapy
dc.subjectadjunctive therapy
dc.subjectTissue Factor
dc.subjectThrombin
dc.subjectcoagulation Factor X
dc.subjectextrinsic pathway of coagulation
dc.titleInvestigating the extrinsic pathway of coagulation as a therapeutic target for severe malaria
dc.typeDissertation
dc.description.degreePhD
dc.description.departmentInfectious Diseases
dc.description.majorInfectious Diseases
dc.description.advisorJulie Moore
dc.description.committeeJulie Moore
dc.description.committeeBalazs Rada
dc.description.committeeTamas Nagy
dc.description.committeePeterson David
dc.description.committeeBenjamin Brainard


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record